mark voskoboynik

[Josh Frydenberg @JoshFrydenberg]

When you firebomb a synagogue with people inside & attack a local restaurant because it’s owned by Jews, it’s NOT about Israel, it’s NOT about protest, it’s a hate crime.

Violent antisemitism is a threat to us all & until it’s called out for what it really is, it will continue!

[Michael Hofman @DrMHofman]

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects

🔥Hot off the press @TheLancetOncol: https://t.co/jBJCOPnxDP

💊Lu-PSMA followed by docetaxel vs. docetaxel alone (130 men randomised)
🎯Undetectable PSA at 1 year: 41% vs 16% (OR 3·88; p=0·0020)
💥No additional side effects with Lu-PSMA
✅Secondary endpoints favour Lu-PSMA as well

🎥Watch it on GU Cast: https://t.co/NZyM9JBrsw

Investigator-led study @AzadOncology @PeterMacCC
Big shout out to @MovemberAUS and all other funders & supporters @CDMRP @UniMelb #VCA #MRFF @ANSTO @Novartis @pros_tic
Thanks to @ANZUPtrials #ARTnet
👏UprontPSMA Study Team all around Australia

[Diwakar Davar, M.D. @diwakardavar]

(1/3) ALPN-202 (davo) is a novel agent that inhibited PD-1/CTLA-4 with PD-L1-dependent CD28 co-stim. Dose-escalated singly (NEON-1) & with pembro (NEON-2). Dose-dependent PK both as mono and combo with moderate ADA incidence (14% vs. 24%). https://t.co/fP5RcSDCQA

[OncoDaily @oncodaily]

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors
@jitcancer @diwakardavar @LudiCa19862 @_vosko @RachelSanbornMD @JustinGainor

#Cancer #OncoDaily #Oncology #CancerCare #CancerResearch

https://t.co/n21zWBcv0K

[Michael Hofman @DrMHofman]

ENZA-P in @TheLancetOncol

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team #ArtNet

https://t.co/DCSGCixZE4

Thanks @MovemberAUS @Novartis for funding

[Louise Emmett @drlouiseemmett]

ENZA-p trial @TheLancetOncol
https://t.co/OSJ6FskZDd
Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC.
Biomarker guided combination therapy works!
Better response depth/duration with no added tox. @ANZUPtrials @TrialsCentre @MovemberAUS @SVHSydney

[Annie Wong 黃毅敏 @anmwongNZ]

The @myESMO leadership course is one of the best things I’ve done

🌏 Focussing on oncology issues for Asia-Pacific region

👥 Comms/leadership skills

🤩 Connecting with new colleagues/friends/ESMO mentors

Apply now 👇

[Ian Davis (Bluesky @profiand) @Prof_IanD]

Highlighting the need for better #diversity in #ClinicalTrials and the need to provide these services where people actually live.
@EHCSMonash @easternhealthau @Monash_FMNHS @ACTA_org @theheraldsun

[Herbert Loong, MBBS, FASCO @herbloong]

Feeling young after being able to snap 📸 a #Wefie with graduates of @myESMO Asia #LGP programme. Thanks mentors including @ravikanesvaran for mentoring a new generation of oncology leaders in our region! @anmwongNZ @PoonEileen @reswong #mentorship #ESMOAsia22

[Hutt Lab @HuttLab]

So exciting to see this new work published on immunotherapy impacts to fertility @NatureCancer. This research strongly advocates we must include reproductive endpoints in clinical trials moving forward! https://t.co/zocPqElZvz

[Louise Emmett @drlouiseemmett]

162/162 randomised on the ENZAp trial. Primary endpoint PSA-PFS enzalutamide vs enzalutamide + Lu PSMA-617. Huge translational side. Matched serial PSMA (FDG) PET, SPECT, RECIST, CTC, ctDNA - prognostic, predictive and interim response biomarkers. Thx everyone involved!

[Nazli Dizman @NazliDizman]

🥁Thrilled to announce that our paper is out @NatureMedicine!

We looked at the impact of nivolumab/ipilimumab +/- #CBM588 a bifidogenic live bacterial product, on gut #Microbiome, serum cytokines & clinical outcomes in #mRCC

🙏🙏@montypal @LuisMezaco @PauloBergerot et al.
1/n🧵

[Toni Choueiri, MD @DrChoueiri]

It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021:

Some negative, some positive, some led to @FDAOncology approval; we learned from all!

Feel free to add & retweet & tag anyone involved

This is not an exhaustive list

@OncoAlert

[Annals of Oncology @Annals_Oncology]

Just out in Annals of Oncology, results of the first-in-human phase 1 study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab. The patient population included anti–PD-1/PD-L1‒refractory NSCLC 🫁 https://t.co/jOatHGRUqi

[Benjamin Besse @BenjaminBesseMD]

LATE PHASE 1 STUDY.
A new highly needed design.

https://t.co/cfdHP9ZVYB

@GustaveRoussy @JcbenitezMD @ArthurGeraud @drcmassard @jsoriamd

[mark voskoboynik @_vosko]

@TommyJohn00 @IASLC @StephenVLiu great interview Tom! Excellent message. As oncologists, for our patients we sometimes have to help find the clarity in the mayhem but we mustn’t forget to look after ourselves 😉

[The Alfred @AlfredHealth]

Cancer patients in Gippsland will have better access to clinical trials locally thanks to a partnership between Alfred Health’s Trialhub and Latrobe Regional Hospital. More: https://t.co/AMXiRHM1Lh

[Arun Azad @AzadOncology]

Congrats to @_vosko & team @AlfredHealth for randomising 1st 2 pts on #UpFrontPSMA! A first-in-field study of #LuPSMA in mHS #ProstateCancer. Thx to funders (@MovemberAUS , MRFF, DoD) and especially patients & families. https://t.co/FsjQOhJvbV

[AlpineImmuneSciences @AlpineImmuneSci]

Dr. Mark Voskobynik @_vosko will be presenting a Trials In Progress poster at #AACR21 on ALPN-202, our first-in-class conditional CD28 costimulator/dual PD-L1/CTLA-4 inhibitor. Learn more about the NEON-1 trial for patients with #cancer. More details: https://t.co/0l0LFmxS6Q

[Sumanta K. Pal, MD, FASCO @montypal]

It's Monday AM post-@ASCO #GU21 & clinic starts in a couple of hours! Lots to process - I'll try to tackle optimal 1L tx for #kidneycancer. I'll make a case for cabo/nivo, leaning on the beautiful (& timely) tables below from @lalaniMD, @SoaresAndrey & @brian_rini (1/15)